FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions

Quick Summary:

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.

---

More Pictures

---

Read Quick SummarySave Time

or

Article Details

Category: EconomyBusiness

Markets: United States

Topics: Health care costs Articles Weight management Cnbc Health care policy LILLY DRN Pharmaceuticals Biotechnology Companies Source:tagname:CNBC US Source Business News Biotech and Pharmaceuticals US: News Health care industry Business Novo Nordisk A/S

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2024-12-24 @ 12:00:02 (22 hours ago)

News Timezone: GMT -5:00

News Source URL: cnbc.com

Language: English

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © CNBC

News ID: 24629641

View Article Analysis

About CNBC

Main Topics: EconomyBusiness

Official Website: cnbc.com

Update Frequency: 3 posts per day

Year Established: 2005

Headquarters: United States

News Last Updated: 18 hours ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT -5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #5

Publisher Details

Frequently Asked Questions